At a glance
ClinicalIndex Comparison RecordN/ACompleted· 409 enrolled
Drug / intervention
Not specified
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Vedolizumab and Anti-TNFs Outcomes in Real-World Biologic Ulcerative Colitis and Crohn's Disease Patients
In Brief
An observational study for Colitis, Ulcerative and Crohn Disease. Completed, enrolled 409 participants across 26 sites in 2 countries.
Detailed Summary
The purpose of this study is to describe treatment patterns associated with first-line and second line biologic use (vedolizumab or other biologic) and to describe the real-world clinical effectiveness of the use (first-line and second line) vedolizumab versus other biologics at least 6 months post-treatment initiation.
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsColitis, Ulcerative, Crohn Disease
CountriesPortugal, Spain
Collaborators--
Timeline
N/ACompletedFinished
20192020202120222023202420252026
First PostedOct 2018
Enrollment StartFeb 2019
Primary CompletionAug 2021
Study CompletionFeb 2022
TodayJul 2026
First PostedOct 18, 2018
Enrollment StartFeb 19, 2019
Primary CompletionAug 23, 2021
Study CompletionFeb 21, 2022
TodayJul 2, 2026
Enrollment to primary: 2.5 yearsPosted 7.7 years ago